AIP
RDHL

ARS Investment Partners’s Redhill Biopharma RDHL Stock Holding History

ARS Investment Partners’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-52
Closed -$240K – 188
2021
Q3 		$240K Sell
52
-38
-42% -$258K 0.02% 139
2021
Q2 		$621K Buy
90
+2
+2% +$13.8K 0.06% 93
2021
Q1 		$643K Buy
88
+10
+13% +$83.9K 0.07% 86
2020
Q4 		$628K Buy
78
+19
+32% +$171K 0.08% 78
2020
Q3 		$600K Buy
+59
New +$484K 0.09% 74

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

ARS Investment Partners's RDHL Position: Q4 2021 in Review

ARS Investment Partners sold out of Redhill Biopharma (RDHL) in Q4 2021, closing a stake of 52 shares — an estimated $240K sold.

ARS Investment Partners first reported a position in RDHL in Q3 2020 and held it in 5 quarters. The position peaked at $643K in Q1 2021. 51 funds tracked by Wall St. Rank hold RDHL as of Q4 2021.

  • ARS Investment Partners reported no remaining Redhill Biopharma position as of Q4 2021 after selling out during the quarter.
  • ARS Investment Partners sold 52 Redhill Biopharma shares in Q4 2021, an estimated $240K.
  • ARS Investment Partners first reported a position in Redhill Biopharma in Q3 2020 and held it in 5 quarters.
  • ARS Investment Partners's Redhill Biopharma position peaked at $643K in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2021.

Based on ARS Investment Partners's 13F filing for Q4 2021, filed 11 Feb 2022.